FDA
-
-
-
-
-
-
-
Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting
-
-
-
-
-
-
-
JPMorgan Downgrades Adicet Bio Inc. (ACET) to Neutral
-
-
-
-
-
-
-
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
-
-
-
-
-
-
-
Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting
-
-
-
-
-
-
-
Pre-Open Stock Movers 03/04: (SG) (FNKO) (GPS) Higher; (OCGN) (SWBI) (VZIO) Lower (more...)
-
-
-
-
-
-
-
Adicet Presents Preclinical Data for ADI-002, a GPC3-Targeted Development Candidate for Solid Tumors, at the SITC Annual Meeting
-
-
-
-
-
-
-
ACETO Corp (ACET) Promotes Blake Aftab to Chief Scientific Officer and Senior VP
-
251,531 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All